Loading clinical trials...
Loading clinical trials...
An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401
Conditions
Interventions
IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
Start Date
November 1, 2014
Primary Completion Date
December 1, 2016
Completion Date
December 1, 2016
Last Updated
January 9, 2018
NCT04274738
NCT01647971
NCT01046006
NCT01125293
NCT00936611
NCT00142116
Lead Sponsor
Idera Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions